Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
NCT00541008
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
92
Enrollment
OTHER
Sponsor class
Conditions
Kidney Cancer
Interventions
DRUG:
sunitinib malate
Sponsor
UNICANCER